Harvard Bioscience (NASDAQ:HBIO) Price Target Cut to $4.50 by Analysts at Benchmark

Harvard Bioscience (NASDAQ:HBIO) had its target price reduced by Benchmark from $5.50 to $4.50 in a research note issued to investors on Monday morning,Benzinga reports. They currently have a speculative buy rating on the medical instruments supplier’s stock.

Harvard Bioscience Trading Down 5.8 %

Shares of HBIO stock opened at $0.60 on Monday. The stock has a 50-day moving average of $1.25 and a 200-day moving average of $1.97. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. The stock has a market cap of $26.40 million, a price-to-earnings ratio of -1.81 and a beta of 1.46. Harvard Bioscience has a 1-year low of $0.59 and a 1-year high of $4.70.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Harvey Partners LLC increased its stake in Harvard Bioscience by 6.2% in the third quarter. Harvey Partners LLC now owns 2,715,000 shares of the medical instruments supplier’s stock valued at $7,303,000 after purchasing an additional 157,500 shares in the last quarter. AMH Equity Ltd increased its position in Harvard Bioscience by 4.7% in the 4th quarter. AMH Equity Ltd now owns 2,500,000 shares of the medical instruments supplier’s stock valued at $5,275,000 after buying an additional 111,132 shares in the last quarter. Royce & Associates LP raised its stake in Harvard Bioscience by 35.4% during the 4th quarter. Royce & Associates LP now owns 1,965,114 shares of the medical instruments supplier’s stock worth $4,146,000 after buying an additional 513,664 shares during the period. Geode Capital Management LLC boosted its holdings in Harvard Bioscience by 2.2% in the third quarter. Geode Capital Management LLC now owns 912,599 shares of the medical instruments supplier’s stock worth $2,455,000 after acquiring an additional 19,972 shares in the last quarter. Finally, State Street Corp boosted its holdings in Harvard Bioscience by 1.1% in the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after acquiring an additional 7,763 shares in the last quarter. Institutional investors and hedge funds own 80.87% of the company’s stock.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.